banner
Together we Drive the Future

講演者



PLENARY KEYNOTE SPEAKERS
Erika Brown

Erika Brown
President & Chief Executive Officer
PALTOWN Development Foundation
Erika Brown
President & Chief Executive Officer
PALTOWN Development Foundation
 
About Speaker: Brown, a Montana native, had a healthy career as a corporate executive search professional until - at age 58 - she was diagnosed with late-stage colorectal cancer. Once her treatment completed, she refocused on the undeveloped niche of disease-specific patient empowerment, founding COLONTOWN on Facebook.COLONTOWN features online, deeply engaged, experience-specific, secret support groups that are exclusively dedicated to CRC patients and family members. The tremendous engagement and energy of COLONTOWN participants have attracted the attention of the media, in particular for the clinical trials groups, which connect patients to the latest treatment options.In 2016, Brown co-founded the PALTOWN Development Foundation to create additional disease-focused communities. COLONTOWN is the model for patient community-building, providing the template for disease communities to follow.Ms. Brown is grateful, empowered, and disease-free - 14 years later.
Scott Durum

Scott Durum
Chief, Section of Cytokines and Immunity
NIH - National Cancer Center - Center for Cancer Research
Scott Durum
Chief, Section of Cytokines and Immunity
NIH - National Cancer Center - Center for Cancer Research
 
About Speaker:

Scott Durum trained in immunology at Wake Forest, Oak Ridge, National Jewish and Yale before coming to the National Cancer Institute, National Institutes of Health. His lab has been interested in the IL-7 pathway for a number of years. Recently, together with collaborators, they found that this is a major pathway driving Acute Lymphoblastic Leukemia, the most common cancer in children. They are working to develop therapeutics directed against the IL-7 pathway in this disease.

Gordon Freeman

Gordon Freeman
Professor, Department of Medical Oncology, Professor of Medicine
Dana Farber Cancer Institute, Harvard University
Gordon Freeman
Professor, Department of Medical Oncology, Professor of Medicine
Dana Farber Cancer Institute, Harvard University
 
About Speaker:

Gordon J. Freeman, PhD works in the Department of Medical Oncology at Dana-Farber Cancer Institute and is Professor of Medicine at Harvard Medical School. Dr. Freeman earned his BA in Biochemistry and Molecular Biology, and PhD in Microbiology and Molecular Genetics from Harvard University. His research has identified the major pathways that control the immune response by inhibiting T cell activation (PD-1/PD-L1 and B7-2/CTLA-4) or stimulating T cell activation (B7-2/CD28).

In 2000, Dr. Freeman discovered PD-L1 and PD-L2, and showed they were ligands for PD-1, thus defining the PD-1 pathway and the drug target: block the interaction. He showed the function of PD-1 was to inhibit immune responses and that blockade enhanced immune responses. He showed that PD-L1 is highly expressed on many solid tumors such as breast and lung, as well as some hematologic malignancies and allows these tumors to inhibit immune attack. He received the 2014 William B. Coley Award for Distinguished Research in Tumor Immunology and 2017 Warren Alpert Foundation award for this work that led to development of PD-1 pathway blockade for cancer immunotherapy.

Michael Karin

Michael Karin
Distinguished Professor, Department of Pharmacology
University of California, San Diego
Michael Karin
Distinguished Professor, Department of Pharmacology
University of California, San Diego
 
About Speaker:

Hepatocellular carcinoma (HCC) is the second leading cause of cancer-related deaths and develops as a result of chronic liver injury and inflammation. The major causes of chronic liver injury are hepatitis B and C virus infections, but in the US and Europe their pathogenic importance has been eclipsed by non-alcoholic (NASH) and alcoholic (ASH) steatohepatitis. Using a novel mouse model developed in our lab, we have shown that NASH pathogenesis and HCC development depend on endoplasmic reticulum (ER) stress, elevated de novo lipogenesis, ballooning degeneration of hepatocytes, induction of TNF expression and hepatic accumulation of p62. NASH and ASH are also associated with upregulation of immunoglobulin A (IgA), first identified in human patients and confirmed in our mouse model. We found that in both human and mouse livers, elevation of circulating IgA is due to accumulation of IgA-producing plasmablasts and plasma cells. These IgA-producing cells express high amounts of PD-ligand 1 (PD-L1) and IL-10 and possess the ability to inhibit activation of HCC-directed cytotoxic CD8+ T lymphocytes (CTL). The inhibition of CTL activation prevents liver protective immunosurveillance, thereby resulting in growth and malignant progression of neoplastic nodules that develop as a result of chronic liver inflammation. Importantly, depletion or ablation of liver IgA-producing cells results in re-invigoration of HCC-directed CTLs, thereby leading to tumor regression. Thus, treatments that inhibit accumulation of liver IgA-producing cells should be effective in preventing progression from NASH and ASH to HCC and inducing regression of established tumors.

Jennifer Towne

Jennifer Towne
Senior Scientific Director
Janssen
Jennifer Towne
Senior Scientific Director
Janssen
 
About Speaker:
Andrew Vandergrift

Andrew Vandergrift
Patient Advocacy Liaison
Ignyta
Andrew Vandergrift
Patient Advocacy Liaison
Ignyta
 
About Speaker:
Cytokines & Inflammation
DISTINGUISHED SPEAKERS
Rachel Caspi

Rachel Caspi
Chief, Immunoregulation Section
NEI, NIH
Rachel Caspi
Chief, Immunoregulation Section
NEI, NIH
 
About Speaker:

Dr. Caspi is is a tenured senior investigator, Section Head and Deputy Chief of the Laboratory of Immunology, National Eye Institute, NIH. She also holds an Adjunct Professorship at the University of Pennsylvannia Sch. Med. Dr. Caspi's research centers on immunology of the eye. A major direction is tolerance and autoimmunity to immunologically privileged retinal antigens in animal models of autoimmune uveitis, a potentially blinding human disease. She developed the mouse model of uveitis, now in use worldwide. Her studies have elucidated many basic mechanisms of pathogenesis and helped to devise clinically relevant immunotherapeutic approaches. Her recent work emphasizes the effects of the commensal microbiome on anti-retinal autoimmunity as well as on mucosal immunity and host defense at the ocular surface. She serves on journal Editorial Boards and is an organizer of ocular and general immunology conferences. Dr. Caspi is the recipient of the highly prestigious Friedenwald award and the Alcon Research Institute award, and has authored and co-authored over 230 publications.

Manoj Dadlani

Manoj Dadlani
Chief Executive Officer
CosmosID
Manoj Dadlani
Chief Executive Officer
CosmosID
 
About Speaker:
John Eid

John Eid
Chief Scientific Officer and Co-Founder
Whole Biome
John Eid
Chief Scientific Officer and Co-Founder
Whole Biome
 
About Speaker:
Ling-Yang Hao

Ling-Yang Hao
Principal Scientist
Janssen
Ling-Yang Hao
Principal Scientist
Janssen
 
About Speaker:
Michael Howell

Michael Howell
Senior Director of Translational Sciences
Incyte Corporation
Michael Howell
Senior Director of Translational Sciences
Incyte Corporation
 
About Speaker:

Michael Howell currently works as the Senior Director of Translational Research at the Incyte Corporation with a focus on immunological diseases. Dr. Howell received his PhD in Immunology from the West Virginia University School of Medicine and then moved onto National Jewish Medical and Research Center where he transitioned from a post doctoral fellow to Assistant Professor in the Division of Allergy and Immunology. While at NJMRC, he served as a Co-Investigator for the Atopic Dermatitis Vaccinia Network and made seminal discoveries in the role of Th2 cytokines on the barrier and innate immune responses of atopic dermatitis patients. Since transitioning to industry, Dr. Howell has held positions at Boehringer Ingelheim, the Immune Tolerance Network, MedImmune, and Incyte. Throughout his career, Dr. Howell has combined clinical and basic science approaches to evaluate inflammatory diseases. This research has been highlighted in national and international meetings, peer-reviewed publications and reviews on immunologic mechanisms and has led to recent patent applications for therapeutic interventions and biomarker strategies in inflammatory diseases.

Xiao Hu

Xiao Hu
Executive Director
Lycera Corp
Xiao Hu
Executive Director
Lycera Corp
 
About Speaker:

Dr. Xiao Hu is currently Executive Director of Biology, head of the immune oncology group at Lycera Corp. He joined Lycera in 2010 bringing extensive experience in drug discovery, particularly around nuclear receptors, metabolic enzymes and gene regulation. Prior to Lycera Dr. Hu was a group and project leader at Pfizer/Pharmacia, where in 10 years he initiated and led multiple projects from idea to clinical testing, resulting in 4 successful IND filings and Phase I trials in inflammation/autoimmune/metabolic diseases. Since joining Lycera, Dr. Hu has held key leadership roles in projects targeting RORgamma for immunotherapy of cancer and for autoimmune diseases. He contributed significantly to the successful completion of Phase I and initiation of II trials of a RORgamma agonist compound in cancer patients. He has also been responsible for initiating and executing multiple new projects targeting novel immune oncology mechanisms.

Dr. Hu is an active member of SITC (Society for Immunotherapy of Cancer) and Endocrine Society. He received his B.S. from University of Science and Technology of China, Ph.D. from Indiana University and completed his postdoctoral training on transcriptional regulation of metabolism at University of Pennsylvania with Dr. Mitchell Lazar.

Alison Humbles

Alison Humbles
Principal Scientist
MedImmune
Alison Humbles
Principal Scientist
MedImmune
 
About Speaker:
Ignacio Juncadella

Ignacio Juncadella
Principal Scientist, Immunology and Respiratory Research
Boehringer Ingelheim
Ignacio Juncadella
Principal Scientist, Immunology and Respiratory Research
Boehringer Ingelheim
 
About Speaker:

Ignacio J. Juncadella currently works as a principal scientist and project leader in the department of Immunology and Respiratory Disease Research at Boehhringer Ingelheim, Inc. His research primarily focuses on the identification and validation of therapeutic concepts related to inflammation, autoimmunity and fibrotic pathways in human disease. Ignacio obtained his Ph.D. from the University of Massachusetts Amherst in 2008. Ignacio joined Boehringer Ingelheim after his postdoctoral training with Dr. Kodi S. Ravichandran at the University of Virginia where he studied mechanisms of tissue tolerance and homeostasis, innate immunity and how defects in apoptotic cell clearance, a process call 'efferocytosis' results in exacerbated lung inflammation.

Dermot McGovern

Dermot McGovern
Joshua L. and Lisa Z. Greer Chair of Inflammatory Bowel genetics, Professor of Medicine
Cedars-Sinai Medical Center, UCLA School of Medicine
Dermot McGovern
Joshua L. and Lisa Z. Greer Chair of Inflammatory Bowel genetics, Professor of Medicine
Cedars-Sinai Medical Center, UCLA School of Medicine
 
About Speaker:
Kingston HG Mills

Kingston HG Mills
Professor of Experimental Immunology
Trinity Biomedical Sciences Institute
Kingston HG Mills
Professor of Experimental Immunology
Trinity Biomedical Sciences Institute
 
About Speaker:

Kingston Mills is Professor of Experimental Immunology, School of Biochemistry and Immunology, Trinity Biomedical Sciences Institute (TBSI), Trinity College Dublin (TCD). He is Head of the Immunology, Inflammation and Infection research theme at TCD and Head of the Centre for the Study of Immunology in TBSI. He trained at as a Postdoctoral Fellow at University College London and the MRC National Institute for Medical Research, Mill Hill, London (now the Crick Institute), before joining the Scientific Staff of National Institute for Biological Standards and Control (NIBSC), Herts, UK. He was appointed to a Personal Chair at TCD in 2001 and was Head of the School of Biochemistry and Immunology from 2008-2011. He is a co-founder of University spin-out companies Opsona Therapeutics and TriMod Therapeutics. His research focuses on the role of the immune system, in particular T cell subtypes, in immunity to infection, cancer and autoimmunity.

Laurence Morel

Laurence Morel
Mary and Ryan Whisenant Family Professor of Pathology
University of Florida
Laurence Morel
Mary and Ryan Whisenant Family Professor of Pathology
University of Florida
 
About Speaker:

Laurence Morel obtained her PhD from the University of Aix-Marseille (France). She trained as a postdoctoral fellow with Dr. Ward Wakeland at the University of Florida (USA) in immunogenetics, where she started to work on the genetic basis of lupus in mouse models. She was appointed with a faculty position in the department of Pathology, Immunology, and Laboratory Medicine at UF in 1999, where she is currently a tenured professor and the Vice Chair for Research and Academic Affairs. Her research focuses on the mechanisms of lupus pathogenesis using mouse models as well as patients' samples. In addition to genetic studies, her studies now extend to immune metabolism, the role of the microbiome, and the contribution of mesenchymal stem cells to lupus pathogenesis. Her long-term goal is to identify genes and pathways responsible for lupus susceptibility, to characterize their contribution to autoimmune immunopathology, and to translate these findings into therapeutic targets.

Cathryn Nagler

Cathryn Nagler
Bunning Food Allergy Professor, Professor of Pathology, Medicine, Pediatrics and the College
The University of Chicago
Cathryn Nagler
Bunning Food Allergy Professor, Professor of Pathology, Medicine, Pediatrics and the College
The University of Chicago
 
About Speaker:

Cathryn Nagler graduated with honors from Barnard College, Columbia University. She obtained her Ph.D. from the Sackler Institute of Biomedical Science at N.Y.U. School of Medicine and did a postdoctoral fellowship at M.I.T. She was Associate Professor of Pediatrics (Immunology) at Harvard Medical School prior to joining the University of Chicago in 2009. She received the inaugural Bunning Food Allergy Professorship in 2011. Dr. Nagler has participated in numerous review panels for the Crohn's and Colitis Foundation of America, NIDDK, NIAID, and Food Allergy Research and Education (FARE). She recently began her second term on FARE's research advisory board. She has served the American Association of Immunologists (AAI) as Section Editor for the Journal of Immunology, Instructor (Mucosal Immunology) for the Introduction to Immunology course and as member of the Program, Clinical Immunology, Publications and Awards Committees. She is the senior editor for Clinical and Translational Immunology for the AAI's new journal ImmunoHorizons. She has also served as an elected Councilor of the Society for Mucosal Immunology and is an Associate Editor of the journal Mucosal Immunology. Dr. Nagler has a long-standing interest in the mechanisms governing tolerance to dietary antigens and the potential immunomodulatory features of the oral route of antigen administration. Her most recent work examines how commensal bacteria regulate susceptibility to allergic responses to food. She has applied insights gained from studying pre-clinical gnotobiotic murine models of cow's milk allergy to launch a new company, ClostraBio, which is developing microbiome-modulating therapeutics for the prevention and treatment of food allergy.

Take Ogawa

Take Ogawa
Director, Business Development
Second Genome
Take Ogawa
Director, Business Development
Second Genome
 
About Speaker:
Stanley Perlman

Stanley Perlman
Professor, Microbiology and Immunology
University of Iowa
Stanley Perlman
Professor, Microbiology and Immunology
University of Iowa
 
About Speaker:

Dr. Perlman currently investigates the pathogenesis of coronavirus-mediated severe human respiratory disease (severe acute respiratory syndrome (SARS) and the Middle East respiratory syndrome (MERS) and of coronavirus-induced demyelination. His laboratory also has a strong interest in the regulatory T cells in the context of infection. He has developed severe animal models for the study of MERS and has also investigated T cell responses in MERS survivors. Prior to joining the faculty of the University of Iowa in 1983, he obtained his Ph.D. at M.I.T. and his M.D. at the University of Miami.

Thomas Schall

Thomas Schall
President and Chief Executive Officer
ChemoCentryx
Thomas Schall
President and Chief Executive Officer
ChemoCentryx
 
About Speaker:
Pejman Soroosh

Pejman Soroosh
Principal Scientist and Head, Immunobiology Research Team (IRT)
Janssen
Pejman Soroosh
Principal Scientist and Head, Immunobiology Research Team (IRT)
Janssen
 
About Speaker:
Howard Spiegel

Howard Spiegel
Simple Plex Specialist
Protein Simple, A Division of Bio-Techne
Howard Spiegel
Simple Plex Specialist
Protein Simple, A Division of Bio-Techne
 
About Speaker:

Howard Spiegel is a reformed bench scientist. He earned his technical skills working under Tony Fauci (when he was a merely a Section Head) making and purifying synthetic peptides. After scoring too low on MCAT and GRE he sold his soul and became a salesman. For the last 30 years Howard has found a way to maintain integrity while serving the research community. Howard joined MesoScale(MSD) in the early days of 2004 and then ProteinSimple (that became Bio-Techne) in 2014. He now takes his work wife (ELLA) on the road and wows scientist with hands-free 90-minute ELISA's.

Immunotherapeutics & Immunomonitoring
DISTINGUISHED SPEAKERS
Brian Champion

Brian Champion
Chief Scientific Officer
PsiOxus Therapeutics
Brian Champion
Chief Scientific Officer
PsiOxus Therapeutics
 
About Speaker:

Dr Brian Champion is Chief Scientific Officer and member of the Executive Management Team at PsiOxus Therapeutics Ltd, Oxford, UK where he is leading the scientific team in the development of novel oncolytic virus-based, tumor-specific immunogene therapies for the treatment of cancer. He was previously Executive Director and Head of Immunology for Pfizer's Vaccine Immunotherapeutics Research Unit in La Jolla, California, leading the immunology team providing expertise and immunoassays for Pfizer vaccine projects, program leader for an anti-IgE therapeutic vaccine for allergy/asthma, and a member of the leadership team. Prior to this he was Site Head for Pfizer Vaccine Research in the UK. Before joining Pfizer, Dr Champion was Chief Scientific Officer for Lorantis and Celldex in Cambridge (UK) developing protein and DNA-based, antigen-specific immunotherapeutic approaches to a variety of immunological diseases, including therapeutic vaccines and immunotherapeutic biomolecule approaches for cancer, infectious diseases, allergies and autoimmune disorders. Prior to Lorantis, he was with Glaxo and GlaxoWellcome (UK and USA) for 13 years, focusing primarily on target discovery and validation research for autoimmune, allergic and bone disorders.

Michael Gresser

Michael Gresser
Chief Scientific Officer
Immungene
Michael Gresser
Chief Scientific Officer
Immungene
 
About Speaker:

Mike Gresser, Ph.D. is Chief Scientific Officer for ImmuneGene. From 2000-2006, Dr. Gresser served as Vice President, Research for Inflammation at Amgen, Inc. Prior to Amgen, he was at the Merck Frosst Center for Therapeutic Research where he rose to be Executive Director of Biochemistry and Molecular Biology. He received his Ph.D in Biochemistry from Brandeis University and did postdoctoral studies at UCLA. Before joining Merck Frosst in 1988 he was Pr ofessor of Chemistry at Simon Frazer University in Burnaby, British Columbia.

Karin Jooss

Karin Jooss
Executive Vice President of Research & Chief Scientific Officer
Gritstone Oncology
Karin Jooss
Executive Vice President of Research & Chief Scientific Officer
Gritstone Oncology
 
About Speaker: Karin Jooss serves as Chief Scientific Officer of Gritstone Oncology. Dr. Jooss joined Gritstone from Pfizer, where she served as head of Cancer Immunotherapeutics within the Vaccine Immunotherapeutics department for seven years. While at Pfizer, she built and led immuno-oncology teams, was a member of the Vaccine Immunotherapeutics leadership team and served as the head of the Immunopharmacology team. Her duties included overseeing the assessment of all cancer vaccine in-licensing opportunities, and developing and launching Pfizer's first clinical cancer vaccine program deploying a variety of vaccine platforms and immune modulators to build a multi-component vaccine-based immunotherapy regimen. Prior to joining Pfizer, Jooss served as vice president of Research at Cell Genesys, Inc. where she oversaw all research activities related to the company's cancer vaccine and oncolytic virotherapy programs. Dr.Jooss received her Ph.D. in Molecular Biology from the University of Marburg in Germany and performed postgraduate work in gene therapy and immunology at the University of Pennsylvania. She is on the editorial board of Molecular Therapy and Journal of Gene Medicine and is a member of the immunology and educational committee for the American Society of Gene Therapy as well as the Industry Task Force of the Society for Immunotherapy of Cancer (SITC).
Joost Oppenheim

Joost Oppenheim
Senior Investigator
NIH NCI
Joost Oppenheim
Senior Investigator
NIH NCI
 
About Speaker:

Dr. Oppenheim pioneered the development of cytokine, chemokine and alarmin fields of research. He is currently studying the role of alarmins that activate toll-like receptors, in inducing immunity to cancer. He has been engaged in translational studies aimed at utilizing alarmins as adjuvants in vaccines for use against infectious agents and tumors. He is also investigating means of blocking the immunosuppressive limb of immunity as exerted by T regulatory cells to augment antitumor immunity. Dr. Oppenheim is the Chief of the Laboratory of Molecular Immunoregulation and the Deputy Director of the Cancer and Inflammation Program at the National Cancer Institute which focuses on the effects of inflammation and the immune response on cancer.

Alexander Rakhmilevich

Alexander Rakhmilevich
Distinguished Scientist
University of Wisconsin-Madison
Alexander Rakhmilevich
Distinguished Scientist
University of Wisconsin-Madison
 
About Speaker:

Dr. Rakhmilevich is a distinguished scientist at the University of W isconsin-Madison. He obtained his MD and PhD degrees in Soviet Union. He has been working in the field of cancer immunology since 1985. His current laboratory research involves the develop ment of cancer immunotherapies using activation of macrophages via CD40 ligation

Blythe Sather

Blythe Sather
Associate Director
Juno Therapeutics
Blythe Sather
Associate Director
Juno Therapeutics
 
About Speaker:

Dr. Blythe Sather received her PhD from the University of Washington, Department of Immunology in 2007. For her thesis, she focused on understanding the role of homing receptors on the function of regulatory T cells in the laboratory of Dr. Danial Campbell at the Benaroya Research Institute in Seattle. During her postdoctoral work at Seattle Children's Research Institute in the laboratory of Dr. David Rawlings, she focused on developing lentiviral gene therapies and lead a team who did ground breaking work using megaTAL nucleases to insert chimeric antigen receptors (CARs) via gene editing-mediated homologous recombination into the CCR5 locus of primary T cells for HIV therapy. In 2014, her desire to bring these types of therapies to the clinic on a larger scale lead her to move to Juno Therapeutics to help develop their research division. Since at Juno, she been instrumental in building their CAR T cell development platform, leading the multiple myeloma CAR T cell program, as well leading the collaboration with Editas medicine to bring CRISPER-mediated gene editing to CAR and TCR T cell products.

Peggy Scherle

Peggy Scherle
Group Vice President of Discovery
Incyte
Peggy Scherle
Group Vice President of Discovery
Incyte
 
About Speaker:

Peggy received her Ph.D. in immunology from the University of Pennsylvania and completed her postdoctoral training at the NIH. Prior to joining Incyte in 2002, Peggy held scientific research positions with DuPont Pharmaceuticals Company and Bristol-Myers Squibb. At Incyte, Peggy has been involved in target validation and drug discovery efforts within the therapeutic areas of inflammation and oncology. Her efforts have focused on the identification and preclinical characterization of small molecule inhibitors of key proteins involved in cell signaling and immune cell function.

Steffen Walter

Steffen Walter
Chief Scientific Officer
Immatics
Steffen Walter
Chief Scientific Officer
Immatics
 
About Speaker:

Dr Walter joined Immatics Biotechnologies GmbH in 2005 where he became VP Immunology. For over 15 years he has been active in the field of cancer immunotherapy and a leader in human T-cell biology. In addition to supporting the development of the XPRESIDENT® technology platform, under his leadership, Immatics developed its powerful Immunomonitoring and T-cell receptor (TCR) discovery platforms to support the generation of safe and effective T-cell-based therapeutic modalities. In 2015, Dr Walter co-founded Immatics US, Inc. in Houston, Texas as a joint venture between Immatics and MD Anderson Cancer Center (MDACC) to develop next-generation adoptive cell therapies (ACT). He contributed significantly to raising the necessary funding including a $20m CPRIT grant by the State of Texas. As CSO, at Immatics US he leads a team that is responsible for Product Science, Process Development, Manufacturing, Quality Control and Program Management for Immatics' cell therapy programs. Dr Walter is an inventor on numerous patents and patent applications and has co-authored more than 30 publications in prestigious peer-reviewed journals including Nature Medicine, Cell Reports, Brain and Blood. Dr Walter gained his PhD in Immunology from the University of Tuebingen, Germany.

Immunogenicity & Immunotoxicity
DISTINGUISHED SPEAKERS
Annie De Groot

Annie De Groot
Founder, CEO & CSO
Epivax, Inc.
Annie De Groot
Founder, CEO & CSO
Epivax, Inc.
 
About Speaker:

Annie De Groot is a Smith College graduate (Class of 1978) and medical doctor trained at the University of Chicago (Pritzker School of Medicine, 1983). She trained in Internal Medicine and Infectious Disease at New England Medical Center, and was a research fellow at the NIH (1986-1989). She has both laboratory bench (NIH) and field (former Zaire, the Gambia, and Mali) experience in vaccine research and vaccination campaigns. Having experienced both the beauty of discovery in bench research and the thrill of improving patient lives in her field and clinical work, she has worked to expand the engagement of bench scientists in clinical work and vice versa, whenever possible.

Following her Infectious Disease Fellowship (NEMC), she became a faculty member at Brown University in 1993, where she began to develop the cutting edge computational vaccine design tools for which she is well known. She licensed the first versions of these tools to EpiVax, Inc. in 1998, formed the company with two partners, and has served as CEO/CSO and President of the company since its inception. With Bill Martin cofounder, she has succeeded in establishing EpiVax as a leading company in the field of immunoinformatics, working with a range of global clients and partners to improve the design of vaccines and biologics and improving human health everywhere.

De Groot moved her academic affiliation from Brown University to University of Rhode Island in 2009. De Groot became Director of the Institute for Immunology and Informatics and was subsequently awarded $13M in funding from the NIH to develop the 'iCubed' as a center of excellence in Computational Vaccinology. She is the author more than 190 peer-reviewed publications in the fields of computational vaccinology, biodefense, personalized vaccines, and immunology.

Since 2016, she and her business partner Bill Martin have been working to establish a new subsidiary of EpiVax, tentatively called Ancer, that will focus on the emerging field of immune-oncology. Ancer will develop personalized cancer vaccines based on the patients' own tumor genome. Should De Groot succeed in translating these concepts to the clinic, she will have realized her lifelong dream, which is to make vaccines that are tailored to the individual, highly efficient, safe, and accessible worldwide. She has won numerous awards, including the Smith Medal in 2013, was recognized as one of the 50 most influential people in vaccinology in 2014 and named Vaccine company CEO of the year in 2016.

Kei Kishimoto

Kei Kishimoto
Chief Scientific Officer
Selecta Biosciences
Kei Kishimoto
Chief Scientific Officer
Selecta Biosciences
 
About Speaker:

Dr. Kishimoto is the Chief Scientific Officer of Selecta Biosciences, a biotechnology company developing synthetic vaccines b ased on a novel self-assembling nanoparticle technology. Prior to joining Selecta, Dr. Kishimoto was Vice President of Research at Momenta Pharmaceuticals where he led multidisciplinary teams in inflammation, oncology, and cardiovascular disease. Previously he was Senior Director of Inflammation Research at Millennium Pharmaceuticals, where he provid ed the scientific leadership for four programs in clinical development, and an Associate Director of Immunology at Boehringer Ingelheim. Dr. Kishimoto receive d his doctoral degree in Immunology from Harvard University and his post-doctoral training at Stanford University.

Eszter Lazar-Molnar

Eszter Lazar-Molnar
Immunology Medical Director
ARUP Laboratories
Eszter Lazar-Molnar
Immunology Medical Director
ARUP Laboratories
 
About Speaker:

Dr. Lazar-Molnar is an assistant professor in the Department of Pathology at the University of Utah School of Medicine. She received her PhD in biological sciences at the Semmelweis University in Budapest, Hungary and completed a postdoctoral fellowship in the laboratory of Dr. Stanley G. Nathenson at the Albert Einstein College of Medicine in Bronx, New York, where she was studying immune regulation through costimulatory molecules and finding new ways for designing immunotherapy. She was the recipient of a Cancer Research Institute postdoctoral fellowship and the Belfer Outstanding Postdoctoral Research Award in 2009. She completed a clinical immunology fellowship at the University of Utah and is currently a medical director in Immunology at ARUP and assistant director of the Histocompatibility & Immunogenetics Laboratory at the University of Utah. Her research interests include cellular immunology, immunotherapy, and transplantation immunology. Dr. Lazar-Molnar is board certified by the American Board of Medical Laboratory Immunology (ABMLI) and American Board of Histocompatibility and Immunologenetics (ABHI).

Hong-Gee Lee

Hong-Gee Lee
Senior Product Manager & Technical Support Scientist
PBL Assay Science
Hong-Gee Lee
Senior Product Manager & Technical Support Scientist
PBL Assay Science
 
About Speaker:
Meina Liang

Meina Liang
Director, Clinical Immunology and Bioanalysis
MedImmune
Meina Liang
Director, Clinical Immunology and Bioanalysis
MedImmune
 
About Speaker:

Dr. Meina Liang has broad experiences in drug development of small molecule and biologics across therapeutic areas, including antibody-drug conjugate and immunotherapy. Dr. Liang is currently director of Clinical Immunology and Bioanalysis at Medimmune, a subsidiary of AstraZeneca. She leads a centralized functional group supporting Medimmune portfolio from preclinical to post marketing, responsible for biomarker development for pharmacodynamics and patient stratification, pharmacokinetics bioanalysis for exposure-response evaluation, in vitro cytokine release testing for safety assessment, and immunogenicity assessment for regulatory submission. Her group also contributes to investigation of mechanism of action and lead selection of candidate drugs as well as development of companion diagnostics. Dr. Liang manages a GLP laboratory and also plays a DMPK project leader role for safety studies and clinical trials. She contributes to global regulatory interactions and submissions, including INDs, CTAs, IMPDs and BLAs.

Prior to joining Medimmune, Dr. Liang was a senior scientist at Abgenix, leading a centralized antibody-screening group for lead selection and characterization of therapeutic antibodies. Before Abgenix, Dr. Liang was a scientist at Berlex Biosciences, supporting small molecule drug discovery and development and played a key role in advancing a chemokine project from concept to clinical trials.

Dr. Liang holds B.S in Pharmacy from Peking University Medical School in China and Ph.D in Pharmacology from Univ. of North Carolina at Chapel Hill. She received postdoctoral training from University of Virginia. Dr. Liang is a co-inventor for a number of patents, has published numerous articles in peer-reviewed journals and has been invited to present at many international conferences.

Zuben Sauna

Zuben Sauna
Principal Investigator, Haematology, Research and Review
CBER, FDA
Zuben Sauna
Principal Investigator, Haematology, Research and Review
CBER, FDA
 
About Speaker:

Zuben Sauna is a Principal Investigator and a Reviewer at the US Food and Drug Administration. His research interests lie in understanding the pharmacogenetic basis of the immune response to proteins used in therapeutic interventions as these affect efficacy and safety. His laboratory exploits a combination of computational, in vitro and ex vivo approaches to understand why some individuals and/or sub-populations develop immune responses while others do not. His work has published extensively in high impact journals such as Nature Biotechnology, Nature Medicine, Science, Science Translational Medicine and Nature Reviews Genetics. He received his Ph.D. from Poona University, India with subsequent training at the National Cancer Institute, Bethesda, USA.

David W. Scott

David W. Scott
Professor of Medicine & Vice Chair for Research, Department of Medicine (MED)
Uniformed Services University of Health Sciences
David W. Scott
Professor of Medicine & Vice Chair for Research, Department of Medicine (MED)
Uniformed Services University of Health Sciences
 
About Speaker:

David W. Scott, Ph.D. is Vice Chair for Research, Department of Medicine, Uniformed Services School of Health Sciences, Bethesda, MD. An alumnus of Antioch College, University of Chicago (MS) and Yale (PhD). Following a fellowship at Oxford University, he held tenured positions at Duke University, University of Rochester, and University of Maryland Medical School. Dr. Scott has contributed to over 200 research papers on immunologic tolerance, and its application in autoimmune diseases, hemophilia and gene therapy. The author of two textbooks, including The Nature of Immunologic Tolerance, he ia recipient of a number of awards, e.g. Distinguished Service Award from the American Association of Immunologists, a Boarhaave Professorship at Leiden University in Holland, and the 2009 Scientific Achievement Award from AAPS.

ABZENA (Speaker TBD)
Speaker TBD

Abzena
 
About Speaker:
Albert J Wong

Albert J Wong
Professor, Cancer Biology Program, Neurosurgery
Stanford University Medical Center
Albert J Wong
Professor, Cancer Biology Program, Neurosurgery
Stanford University Medical Center
 
About Speaker:

Dr. Wong received his M.D. from the Johns Hopkins School of Medicine. He did a postdoctoral fellowship at the Hopkins Oncology Center under Dr. Bert Vogelstein and then held faculty positions at the Fox Chase Cancer Center and the Thomas Jefferson University before joining the Cancer Biology Program and the Dept. of Neurosurgery at Stanford University in 2005. Focusing on the causes and immunotherapy of human brain tumors, Dr. Wong has made several key discoveries, including the identification of the EGFRvIII alteration and the Gab1 signaling molecule. He showed that EGFRvIII can be used as a vaccine to treat brain tumors, which has led to several clinical trials. This led him to found the biotech company Alteris Therapeutics and as its President led its successful acquisition by Celldex Therapeutics. He has served on numerous review committees for the NIH and ACS, has been an advisor to several universities and pharmaceutical companies, and has been recognized with several honors, including Who's Who in America, and finalist for regional Biotech Company of the Year.